BioMarin Pharmaceutical stock received updates on July 18, 2026, including a price target boost from Citigroup, reported by Benzinga.
7 reports, 3 independent
Updated Nov 3
Gone quiet
- Reports
- 7
- Developments
- 2
- Repetition
- 71%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioMarin Pharmaceutical stock received updates on July 18, 2026, including a price target boost from Citigroup, reported by Benzinga.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.RBC and Citigroup issued new price target updates for BioMarin stock.1 source
Citigroup boosted the price target for BioMarin stock on July 18, 2026.1 source
Keep exploring
The entities involved
-
BioMarin Pharmaceutical
American company
Nothing else this week.
-
Benzinga
American news channel
-
Citigroup
American investment bank and financial services corporation
Related events
- Benzinga reported stock analyst updates concerning the company Freshworks.
- Affirm received analyst rating updates from Susquehanna and Citigroup, with Benzinga reporting the changes.
- Benzinga reported on price target changes involving Annaly Capital Management.
- Citigroup reduced its price objective for ProKidney, with stock changes and ratings reported by Benzinga and MarketBeat.
- Financial institutions Morgan Stanley, Royal Bank of Canada, and Citigroup issued various rating and price target updates for Howmet Aerospace.